Royal Prince Alfred Hospital Sydney Australia.
Heart Research Institute Sydney Australia.
J Am Heart Assoc. 2021 Jan 5;10(1):e018993. doi: 10.1161/JAHA.120.018993. Epub 2020 Dec 21.
Background Release of neutrophil extracellular traps (NETs) after percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) is associated with periprocedural myocardial infarction, as a result of microvascular obstruction via pro-inflammatory and prothrombotic pathways. Colchicine is a well-established anti-inflammatory agent with growing evidence to support use in patients with coronary disease. However, its effects on post-PCI NET formation in ACS have not been explored. Methods and Results Sixty patients (40 ACS; 20 stable angina pectoris) were prospectively recruited and allocated to colchicine or no treatment. Within 24 hours of treatment, serial coronary sinus blood samples were collected during PCI. Isolated neutrophils from 10 patients with ACS post-PCI and 4 healthy controls were treated in vitro with colchicine (25 nmol/L) and stimulated with either ionomycin (5 μmol/L) or phorbol 12-myristate 13-acetate (50 nmol/L). Extracellular DNA was quantified using Sytox Green and fixed cells were stained with Hoechst 3342 and anti-alpha tubulin. Baseline characteristics were similar across both treatment and control arms. Patients with ACS had higher NET release versus patients with stable angina pectoris (<0.001), which was reduced with colchicine treatment (area under the curve: 0.58 versus 4.29; <0.001). In vitro, colchicine suppressed unstimulated (<0.001), phorbol 12-myristate 13-acetate-induced (=0.009) and ionomycin-induced (=0.002) NET formation in neutrophils isolated from patients with ACS post-PCI, but not healthy controls. Tubulin organization was impaired in neutrophils from patients with ACS but was restored by colchicine treatment. Conclusions Colchicine suppresses NET formation in patients with ACS post-PCI by restoring cytoskeletal dynamics. These findings warrant further investigation in randomized trials powered for clinical end points. Registration URL: https://anzctr.org.au; Unique identifier: ACTRN12619001231134.
急性冠状动脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)后释放中性粒细胞胞外诱捕网(NETs)与围手术期心肌梗死有关,其通过促炎和促血栓形成途径导致微血管阻塞。秋水仙碱是一种成熟的抗炎药物,越来越多的证据支持其用于冠心病患者。然而,其在 ACS 患者 PCI 后 NET 形成中的作用尚未得到探索。
前瞻性招募了 60 名患者(40 名 ACS;20 名稳定型心绞痛),并将其随机分配至秋水仙碱治疗组或无治疗组。在治疗后 24 小时内,在 PCI 期间连续采集冠状动脉窦血样。从 10 名 ACS 患者 PCI 后的分离中性粒细胞和 4 名健康对照中,用秋水仙碱(25nmol/L)体外处理,并用离子霉素(5μmol/L)或佛波醇 12-肉豆蔻酸 13-乙酸盐(50nmol/L)刺激。使用 Sytox Green 定量测定细胞外 DNA,并用 Hoechst 3342 固定细胞,并染色抗微管蛋白。两种治疗和对照组的基线特征相似。与稳定型心绞痛患者相比,ACS 患者的 NET 释放更高(<0.001),而秋水仙碱治疗降低了 NET 释放(曲线下面积:0.58 对 4.29;<0.001)。体外,秋水仙碱抑制了 ACS 患者 PCI 后分离的中性粒细胞的未刺激(<0.001)、佛波醇 12-肉豆蔻酸 13-乙酸盐诱导(=0.009)和离子霉素诱导(=0.002)的 NET 形成,但对健康对照没有影响。ACS 患者中性粒细胞的微管蛋白组织受损,但秋水仙碱治疗后得到恢复。
秋水仙碱通过恢复细胞骨架动力学来抑制 ACS 患者 PCI 后 NET 的形成。这些发现为旨在针对临床终点的随机试验提供了进一步研究的依据。